You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
|
|---|---|
| Published in |
The Lancet, November 2012
|
| DOI | 10.1016/s0140-6736(12)61768-1 |
| Pubmed ID | |
| Authors |
Alasdair J Coles, Cary L Twyman, Douglas L Arnold, Jeffrey A Cohen, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Tamara Miller, Elizabeth Fisher, Rupert Sandbrink, Stephen L Lake, David H Margolin, Pedro Oyuela, Michael A Panzara, D Alastair S Compston, for the CARE-MS II investigators |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 15% |
| United States | 2 | 10% |
| United Kingdom | 2 | 10% |
| Switzerland | 1 | 5% |
| Gibraltar | 1 | 5% |
| Argentina | 1 | 5% |
| Unknown | 10 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 80% |
| Scientists | 2 | 10% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 770 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | <1% |
| Portugal | 2 | <1% |
| Netherlands | 2 | <1% |
| Spain | 2 | <1% |
| Argentina | 2 | <1% |
| Brazil | 2 | <1% |
| France | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Germany | 1 | <1% |
| Other | 7 | <1% |
| Unknown | 747 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 118 | 15% |
| Student > Bachelor | 86 | 11% |
| Student > Ph. D. Student | 84 | 11% |
| Other | 81 | 11% |
| Student > Master | 70 | 9% |
| Other | 163 | 21% |
| Unknown | 168 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 296 | 38% |
| Neuroscience | 79 | 10% |
| Agricultural and Biological Sciences | 51 | 7% |
| Biochemistry, Genetics and Molecular Biology | 30 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 26 | 3% |
| Other | 72 | 9% |
| Unknown | 216 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 644. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2023.
All research outputs
#34,431
of 26,017,215 outputs
Outputs from The Lancet
#731
of 43,155 outputs
Outputs of similar age
#123
of 206,812 outputs
Outputs of similar age from The Lancet
#4
of 431 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 43,155 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 67.9. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,812 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 431 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.